Corcept Therapeutics (NASDAQ:CORT) Price Target Cut to $137.00 by Analysts at Canaccord Genuity Group

Key Points

• Analysts at Canaccord Genuity Group have reduced their price target for Corcept Therapeutics from $142.00 to $137.00, maintaining a "buy" rating, which suggests a potential upside of 98.57% from its current stock price.
• Corcept Therapeutics reported a $0.29 EPS for the last quarter, exceeding analysts' expectations, although revenue fell short of estimates at $194.43 million.
• Recent insider trading includes CEO Joseph K. Belanoff selling shares worth approximately $45,319, while corporate insiders collectively sold 173,038 shares during the last quarter.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) had its price objective cut by stock analysts at Canaccord Genuity Group from $142.00 to $137.00 in a research note issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the biotechnology company's stock. Canaccord Genuity Group's target price would indicate a potential upside of 98.57% from the stock's current price.

A number of other research analysts also recently issued reports on CORT. Truist Financial set a $135.00 target price on shares of Corcept Therapeutics in a research report on Tuesday, May 6th. HC Wainwright cut their target price on shares of Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Piper Sandler cut their target price on shares of Corcept Therapeutics from $131.00 to $121.00 and set an "overweight" rating on the stock in a research report on Friday. Finally, Wall Street Zen cut shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Corcept Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $134.50.

Corcept Therapeutics Price Performance

Shares of CORT stock traded up $1.82 during trading hours on Friday, reaching $68.99. The stock had a trading volume of 645,560 shares, compared to its average volume of 1,366,292. The firm has a market capitalization of $7.32 billion, a PE ratio of 59.15 and a beta of 0.15. The firm has a 50-day simple moving average of $71.81 and a 200-day simple moving average of $68.21. Corcept Therapeutics has a twelve month low of $32.33 and a twelve month high of $117.33.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.06. Corcept Therapeutics had a net margin of 19.33% and a return on equity of 20.40%. The company had revenue of $194.43 million for the quarter, compared to analyst estimates of $199.40 million. During the same quarter last year, the firm posted $0.32 earnings per share. The company's quarterly revenue was up 18.7% compared to the same quarter last year. On average, equities analysts anticipate that Corcept Therapeutics will post 1.36 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Joseph K. Belanoff sold 615 shares of the firm's stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $73.69, for a total value of $45,319.35. Following the sale, the chief executive officer directly owned 2,901,370 shares in the company, valued at approximately $213,801,955.30. This trade represents a 0.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sean Maduck sold 473 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $73.44, for a total transaction of $34,737.12. Following the completion of the transaction, the insider owned 17,705 shares of the company's stock, valued at approximately $1,300,255.20. This trade represents a 2.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 173,038 shares of company stock worth $13,237,621 in the last quarter. Corporate insiders own 20.80% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Brooklyn Investment Group increased its stake in shares of Corcept Therapeutics by 99.5% in the 1st quarter. Brooklyn Investment Group now owns 373 shares of the biotechnology company's stock valued at $43,000 after acquiring an additional 186 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in Corcept Therapeutics by 102.0% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 620 shares of the biotechnology company's stock valued at $71,000 after purchasing an additional 313 shares in the last quarter. Covestor Ltd boosted its holdings in Corcept Therapeutics by 1,741.2% during the first quarter. Covestor Ltd now owns 626 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 592 shares during the last quarter. IFP Advisors Inc boosted its holdings in Corcept Therapeutics by 1,150.8% during the first quarter. IFP Advisors Inc now owns 738 shares of the biotechnology company's stock worth $84,000 after purchasing an additional 679 shares during the last quarter. Finally, USA Financial Formulas purchased a new position in shares of Corcept Therapeutics in the 2nd quarter worth about $56,000. Institutional investors own 93.61% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.